WSBCO
WESBANCO INC
$25.32
-0.20%
$2.4B
No data for this timeframe.
Vol
Market Cap$2.4B
Cap SizeMid Cap
SEC Reports5
Recent Activity
May 4, 2026
SEC
WesBanco filed an 8-K furnishing an investor presentation covering Q1 2026 results and 2026 outlook. Adjusted EPS of $0.
8-K — Impact 4/10
Apr 21, 2026
SEC
WesBanco reported strong Q1 2026 earnings with GAAP EPS of $0.88, a significant rebound from a $0.15 loss in the year-ag
8-K — Impact 8/10
Apr 21, 2026
SEC
WesBanco announced it will release Q1 2026 earnings on April 21, 2026, followed by a conference call on April 22. The fi
8-K — Impact 3/10
Analyst Ratings
3Strong Buy
7Buy
4Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
8-K
4/10
WesBanco filed an 8-K furnishing an investor presentation covering Q1 2026 results and 2026 outlook. Adjusted EPS of $0.
May 4, 2026
BULLISH
8-K
8/10
WesBanco reported strong Q1 2026 earnings with GAAP EPS of $0.88, a significant rebound from a $0.15 loss in the year-ag
Apr 21, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.6/10.
NEUTRAL
8-K
4/10
WesBanco filed an 8-K furnishing an investor presentation covering Q1 2026 results and 2026 outlook.
May 4, 2026
BULLISH
8-K
8/10
WesBanco reported strong Q1 2026 earnings with GAAP EPS of $0.88, a significant rebound from a $0.15
Apr 21, 2026
NEUTRAL
8-K
3/10
WesBanco announced it will release Q1 2026 earnings on April 21, 2026, followed by a conference call
Apr 21, 2026
NEUTRAL
DEFA14A
4/10
Wesbanco, Inc. issued a definitive proxy statement in response to Glass Lewis recommending a vote AG
Apr 8, 2026
NEUTRAL
DEFA14A
4/10
Wesbanco is soliciting shareholder approval for the 2025 compensation of its named executive officer
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 71% buy across 14 analysts — 3 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | 2.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | 5.2% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.1B | 10.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.2B | 8.0% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| May 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| Apr 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| Mar 1, 2026 | 3 | 7 | 4 | 0 | 0 | 71% | |
| Feb 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Jan 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.